GlassScriptPhysician profile
Megan Nelson
NPI 1174646053
$2,546.57
in general payments reported to CMS, 2019-2025
35 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $176 · 2021: $126 · 2022: $14.56 · 2023: $602 · 2024: $489 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658 · Education: $50.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.57 |
| Education | $50.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $569.66 | 2019-2025 | Optune, Optune Gio |
| Merck Sharp & Dohme LLC | $236.40 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $173.62 | 2021-2024 | Verzenio, Jaypirca |
| Jazz Pharmaceuticals INC. | $165.04 | 2019-2025 | |
| Merz North America, INC. | $152.26 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $140.07 | 2023-2025 | Dysport |
| Genzyme Corporation | $126.00 | 2020 | |
| Incyte Corporation | $115.64 | 2022-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $89.44 | 2019-2025 | Rybrevant, Tremfya, Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.36 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $69.86 | 2024-2025 | Entyvio, Gattex, Alunbrig |
| Stemline Therapeutics INC. | $54.61 | 2023-2024 | Orserdu |
| Eisai INC. | $48.68 | 2025 | |
| Azurity Pharmaceuticals, INC. | $43.64 | 2023-2024 | Gliadel, Vivimusta |
| Regeneron Healthcare Solutions, INC. | $42.96 | 2024-2025 | Libtayo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $36.86 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $34.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $32.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $31.51 | 2025 | Opdivo |
| Syndax Pharmaceuticals, INC. | $29.13 | 2025 | Revuforj |
| Arbor Pharmaceuticals, INC. | $26.41 | 2021 | |
| Tersera Therapeutics LLC | $26.27 | 2025 | Zoladex |
| Pfizer INC. | $24.20 | 2024 | |
| Coherus Oncology, INC. | $21.68 | 2023 | |
| Seagen INC. | $20.89 | 2023 | Tukysa |
| Amgen INC. | $19.98 | 2025 | |
| Averitas Pharma INC. | $19.80 | 2023 | Qutenza |
| Pharmacosmos Therapeutics INC. | $18.26 | 2023 | Monoferric |
| G1 Therapeutics, INC. | $17.79 | 2023 | Cosela |
| Genentech USA, INC. | $16.98 | 2024 | Tecentriq |
| Abbvie INC. | $16.24 | 2024 | |
| Clovis Oncology, INC. | $15.25 | 2019 | |
| Springworks Therapeutics, INC. | $14.73 | 2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $13.20 | 2019 | |
| Aurobindo Pharma USA, INC. | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.